Shamkani Farnaz, Barzi Seyed Mahmoud, Badmasti Farzad, Chiani Mohsen, Mirabzadeh Esmat, Zafari Mahdi, Shafiei Morvarid
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Department of Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran.
Int Immunopharmacol. 2023 Feb;115:109551. doi: 10.1016/j.intimp.2022.109551. Epub 2023 Jan 6.
Acinetobacter baumannii is a worldwide health issue in terms of its high antibiotic resistance and ability to form biofilms. Nanoparticles (NPs) with high biocompatibility, high penetrating ability, and low medication dose can successfully treat the antibiotic-resistant infections. In this research, the anti-biofilm activity of niosomes containing minocycline and gallium nitrate (GaN) against A. baumannii biofilm was determined. In order to improve their anti-biofilm properties, minocycline and GaN were encapsulated in niosomes as biocompatible drug carriers. The niosomes' size, zeta potential, shape, stability, drug entrapment efficacy, drug release pattern and antibacterial activity were assessed. Several clinical samples were isolated from the lungs of patients hospitalized at Loghman hospital, Tehran, Iran. The biofilm formation of most lethal clinical isolates of A. baumannii was analyzed. The pneumonia model was generated by intranasally administering A. baumannii suspension to anesthetized mice whose immune systems was compromised twice by cyclophosphamide. Lung infection of the mouse with A. baumannii was confirmed using PCR. After treatment, the lungs were excised under sterile conditions and stained with hematoxylin and eosin (H&E) to determine histological symptoms, inflammation and intercellular secretions. The niosomes contained minocycline and GaN had an average size of 230 nm and a zeta potential of -40 mV, respectively. The percentage of drug entrapment and delayed drug release was both high in niosomal formulations. Niosomes containing minocycline and GaN dispersed 1, 3 and 5 day old biofilms. The mice given the combination of two compounds required less time to be treated than the animals given the single medication (minocycline). The minocycline& GaN-loaded niosomes could be considered as promising candidates to treat the infections caused by A. baumannii biofilm.
鲍曼不动杆菌因其高抗生素耐药性和形成生物膜的能力而成为一个全球性的健康问题。具有高生物相容性、高穿透能力和低药物剂量的纳米颗粒(NPs)能够成功治疗抗生素耐药性感染。在本研究中,测定了含有米诺环素和硝酸镓(GaN)的囊泡对鲍曼不动杆菌生物膜的抗生物膜活性。为了提高其抗生物膜性能,将米诺环素和GaN封装在作为生物相容性药物载体的囊泡中。评估了囊泡的大小、zeta电位、形状、稳定性、药物包封率、药物释放模式和抗菌活性。从伊朗德黑兰洛格曼医院住院患者的肺部分离出多个临床样本。分析了鲍曼不动杆菌最致命临床分离株的生物膜形成情况。通过向免疫系统因环磷酰胺两次受损的麻醉小鼠鼻内注射鲍曼不动杆菌悬液建立肺炎模型。使用PCR确认小鼠肺部感染鲍曼不动杆菌。治疗后,在无菌条件下切除肺部并用苏木精和伊红(H&E)染色,以确定组织学症状、炎症和细胞间分泌物。含有米诺环素和GaN的囊泡平均大小分别为230 nm,zeta电位为 -40 mV。在囊泡制剂中,药物包封率和药物缓释率都很高。含有米诺环素和GaN的囊泡可分散1、3和5日龄的生物膜。给予两种化合物组合的小鼠比给予单一药物(米诺环素)的动物所需的治疗时间更短。负载米诺环素和GaN的囊泡可被认为是治疗鲍曼不动杆菌生物膜引起的感染的有前途的候选物。